Titre : Désensibilisation immunologique

Désensibilisation immunologique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Inactivating Agents
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Désensibilisation immunologique : Questions médicales les plus fréquentes", "headline": "Désensibilisation immunologique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Désensibilisation immunologique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Désensibilisation immunologique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Immunosuppression thérapeutique", "url": "https://questionsmedicales.fr/mesh/D007165", "about": { "@type": "MedicalCondition", "name": "Immunosuppression thérapeutique", "code": { "@type": "MedicalCode", "code": "D007165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E05.478.610" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Immunothérapie sublinguale", "alternateName": "Sublingual Immunotherapy", "url": "https://questionsmedicales.fr/mesh/D063729", "about": { "@type": "MedicalCondition", "name": "Immunothérapie sublinguale", "code": { "@type": "MedicalCode", "code": "D063729", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E05.478.610.310.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Désensibilisation immunologique", "alternateName": "Desensitization, Immunologic", "code": { "@type": "MedicalCode", "code": "D003888", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Clare Stokes", "url": "https://questionsmedicales.fr/author/Clare%20Stokes", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA." } }, { "@type": "Person", "name": "Roger L Papke", "url": "https://questionsmedicales.fr/author/Roger%20L%20Papke", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA." } }, { "@type": "Person", "name": "Hye-Ryun Kang", "url": "https://questionsmedicales.fr/author/Hye-Ryun%20Kang", "affiliation": { "@type": "Organization", "name": "Seoul National University Hospital Regional Pharmacovigilance Center, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: helenmed@snu.ac.kr." } }, { "@type": "Person", "name": "Ganesh A Thakur", "url": "https://questionsmedicales.fr/author/Ganesh%20A%20Thakur", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, 02115, USA." } }, { "@type": "Person", "name": "Marija Rowane", "url": "https://questionsmedicales.fr/author/Marija%20Rowane", "affiliation": { "@type": "Organization", "name": "Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37149117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clim.2023.109629" } }, { "@type": "ScholarlyArticle", "name": "Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36732204", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.blre.2023.101041" } }, { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35945604", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02126-2" } }, { "@type": "ScholarlyArticle", "name": "Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.", "datePublished": "2022-10-06", "url": "https://questionsmedicales.fr/article/36201560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pntd.0010809" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Techniques d'investigation", "item": "https://questionsmedicales.fr/mesh/D008919" }, { "@type": "ListItem", "position": 3, "name": "Techniques immunologiques", "item": "https://questionsmedicales.fr/mesh/D007158" }, { "@type": "ListItem", "position": 4, "name": "Immunosuppression thérapeutique", "item": "https://questionsmedicales.fr/mesh/D007165" }, { "@type": "ListItem", "position": 5, "name": "Désensibilisation immunologique", "item": "https://questionsmedicales.fr/mesh/D003888" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Désensibilisation immunologique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Désensibilisation immunologique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Désensibilisation immunologique", "description": "Comment diagnostiquer une allergie ?\nQuels sont les symptômes d'une allergie ?\nQuand envisager la désensibilisation ?\nQuels tests pour évaluer la gravité d'une allergie ?\nLes antécédents médicaux sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Désensibilisation immunologique", "description": "Quels sont les symptômes courants d'une allergie ?\nComment se manifestent les allergies alimentaires ?\nLes symptômes peuvent-ils varier selon l'âge ?\nLes symptômes d'allergie sont-ils toujours immédiats ?\nComment différencier une allergie d'un rhume ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Désensibilisation immunologique", "description": "Comment prévenir les allergies ?\nLes tests d'allergie sont-ils préventifs ?\nL'éducation des patients est-elle importante ?\nLes changements alimentaires peuvent-ils prévenir les allergies ?\nLes vaccinations aident-elles à prévenir les allergies ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Désensibilisation immunologique", "description": "Quels traitements existent pour les allergies ?\nComment fonctionne la désensibilisation ?\nLa désensibilisation est-elle efficace ?\nQuels sont les effets secondaires de la désensibilisation ?\nCombien de temps dure le traitement de désensibilisation ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Désensibilisation immunologique", "description": "Quelles sont les complications possibles des allergies ?\nL'asthme peut-il être causé par des allergies ?\nLes allergies peuvent-elles affecter la qualité de vie ?\nQuelles sont les conséquences d'une anaphylaxie ?\nLes allergies peuvent-elles causer des troubles du sommeil ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Désensibilisation immunologique", "description": "Quels sont les facteurs de risque d'allergies ?\nL'âge influence-t-il le risque d'allergies ?\nLe mode de vie affecte-t-il le risque d'allergies ?\nLes allergies sont-elles héréditaires ?\nL'exposition à la pollution augmente-t-elle le risque d'allergies ?", "url": "https://questionsmedicales.fr/mesh/D003888?mesh_terms=Complement+Inactivating+Agents&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une allergie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests cutanés ou des analyses sanguines pour identifier les allergènes." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une allergie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent démangeaisons, éruptions cutanées, éternuements et difficultés respiratoires." } }, { "@type": "Question", "name": "Quand envisager la désensibilisation ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La désensibilisation est envisagée lorsque les allergies provoquent des symptômes sévères ou persistants." } }, { "@type": "Question", "name": "Quels tests pour évaluer la gravité d'une allergie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de provocation peuvent être réalisés pour évaluer la gravité des réactions allergiques." } }, { "@type": "Question", "name": "Les antécédents médicaux sont-ils importants ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents médicaux aident à identifier les allergies et à orienter le traitement." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une allergie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent rhinite, conjonctivite, urticaire et anaphylaxie dans les cas graves." } }, { "@type": "Question", "name": "Comment se manifestent les allergies alimentaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies alimentaires peuvent provoquer des vomissements, des douleurs abdominales et des éruptions cutanées." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils varier selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon l'âge et la sensibilité individuelle à l'allergène." } }, { "@type": "Question", "name": "Les symptômes d'allergie sont-ils toujours immédiats ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains symptômes peuvent apparaître plusieurs heures après l'exposition à l'allergène." } }, { "@type": "Question", "name": "Comment différencier une allergie d'un rhume ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies provoquent des démangeaisons et des éternuements en continu, contrairement au rhume." } }, { "@type": "Question", "name": "Comment prévenir les allergies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les allergènes connus et maintenir un environnement propre peut aider à prévenir les allergies." } }, { "@type": "Question", "name": "Les tests d'allergie sont-ils préventifs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests d'allergie peuvent aider à identifier les allergènes et à éviter les expositions." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation aide les patients à reconnaître et à éviter les déclencheurs d'allergies." } }, { "@type": "Question", "name": "Les changements alimentaires peuvent-ils prévenir les allergies ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des changements alimentaires peuvent réduire le risque d'allergies alimentaires chez certains individus." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir les allergies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent réduire le risque de développer des allergies, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "Quels traitements existent pour les allergies ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les antihistaminiques, les corticostéroïdes et la désensibilisation." } }, { "@type": "Question", "name": "Comment fonctionne la désensibilisation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La désensibilisation expose progressivement le patient à l'allergène pour réduire la réaction immunitaire." } }, { "@type": "Question", "name": "La désensibilisation est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est efficace pour de nombreuses allergies, notamment aux pollens et aux acariens." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la désensibilisation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des démangeaisons, des rougeurs et des réactions allergiques légères." } }, { "@type": "Question", "name": "Combien de temps dure le traitement de désensibilisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut durer de plusieurs mois à plusieurs années, selon l'allergène et la réponse du patient." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des allergies ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anaphylaxie, l'asthme et des infections secondaires dues à des grattages." } }, { "@type": "Question", "name": "L'asthme peut-il être causé par des allergies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les allergies peuvent déclencher ou aggraver l'asthme chez certaines personnes." } }, { "@type": "Question", "name": "Les allergies peuvent-elles affecter la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les allergies non traitées peuvent réduire la qualité de vie en provoquant des symptômes chroniques." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une anaphylaxie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "L'anaphylaxie peut entraîner un choc, une perte de conscience et nécessite une intervention médicale immédiate." } }, { "@type": "Question", "name": "Les allergies peuvent-elles causer des troubles du sommeil ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes d'allergie peuvent perturber le sommeil, entraînant fatigue et irritabilité." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'allergies ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, l'exposition à des allergènes et des conditions environnementales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'allergies ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'allergies peut varier selon l'âge, avec une prévalence plus élevée chez les enfants." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque d'allergies ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque d'allergies." } }, { "@type": "Question", "name": "Les allergies sont-elles héréditaires ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents familiaux d'allergies augmentent le risque de développer des allergies." } }, { "@type": "Question", "name": "L'exposition à la pollution augmente-t-elle le risque d'allergies ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la pollution de l'air peut exacerber les allergies et augmenter leur prévalence." } } ] } ] }

Sources (10000 au total)

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement act...

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.

The efficacy and safety of complement inhibition in COVID-19 patients is unclear.... A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO... 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea... Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...

Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.

Enteroaggregative Escherichia coli (EAEC) is a predominant but neglected enteric pathogen implicated in infantile diarrhoea and nutrient malabsorption. There are no non-antibiotic approaches to dealin... We used EAEC strains, 042 and MND005E in a medium-throughput crystal violet-based antibiofilm screen. Hits were confirmed in concentration-dependence, growth kinetic and time course assays and activit... In all, five compounds (1.25%) reproducibly inhibited biofilm accumulation by at least one strain by 30-85% while inhibiting growth by under 10%. Hits exhibited potent antibiofilm activity at concentr... This study identified five compounds, not previously described as anti-adhesins or Gram-negative antibacterials, with significant EAEC antibiofilm activity. Molecule, MMV687800 targets the EAEC Aap. I...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.

We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future num...

Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.

A male in his teens with a history of liver transplant for biliary atresia (aged 2 years) and autoimmune haemolytic anaemia (AIHA, aged 6 years) presented with jaundice, dark urine, fatigue and chest ...

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. This post hoc analys... Patients with PNH and hemoglobin ≥10.0 g/dL at baseline of PADDOCK (N = 6), PRINCE (N = 8), and PEGASUS (N = 11) were included. Before receiving pegcetacoplan, PADDOCK and PRINCE patients were C5i-nai... From baseline to week 16, mean (SD) hemoglobin concentrations increased in C5i-naive patients (PADDOCK: 10.5 [0.4] to 12.7 [1.1] g/dL; PRINCE: 11.3 [1.0] to 14.0 [1.3] g/dL) and those with suboptimal ... Patients with PNH and mild/moderate anemia who were C5i-naive or who had suboptimal hemoglobin concentrations despite eculizumab treatment had improved hematologic outcomes and reduced fatigue after i... Trial registration numbers: PADDOCK (NCT02588833), PRINCE (NCT04085601; EudraCT, 2018-004220-11), PEGASUS (NCT03500549)....